Literature DB >> 25964995

The Tipper-Strominger Hypothesis and Triggering of Allostery in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus (MRSA).

Jennifer Fishovitz1, Negin Taghizadeh1, Jed F Fisher1, Mayland Chang1, Shahriar Mobashery1.   

Abstract

The transpeptidases involved in the synthesis of the bacterial cell wall (also known as penicillin-binding proteins, PBPs) have evolved to bind the acyl-D-Ala-D-Ala segment of the stem peptide of the nascent peptidoglycan for the physiologically important cross-linking of the cell wall. The Tipper-Strominger hypothesis stipulates that β-lactam antibiotics mimic the acyl-D-Ala-D-Ala moiety of the stem and, thus, are recognized by the PBPs with bactericidal consequences. We document that this mimicry exists also at the allosteric site of PBP2a of methicillin-resistant Staphylococcus aureus (MRSA). Interactions of different classes of β-lactam antibiotics, as mimics of the acyl-D-Ala-D-Ala moiety at the allosteric site, lead to a conformational change, across a distance of 60 Å to the active site. We directly visualize this change using an environmentally sensitive fluorescent probe affixed to the protein loops that frame the active site. This conformational mobility, documented in real time, allows antibiotic access to the active site of PBP2a. Furthermore, we document that this allosteric trigger enables synergy between two different β-lactam antibiotics, wherein occupancy at the allosteric site by one facilitates occupancy by a second at the transpeptidase catalytic site, thus lowering the minimal-inhibitory concentration. This synergy has important implications for the mitigation of facile emergence of resistance to these antibiotics by MRSA.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25964995      PMCID: PMC4686766          DOI: 10.1021/jacs.5b01374

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  44 in total

1.  Pharmacokinetic/pharmacodynamic assessment of the in-vivo efficacy of imipenem alone or in combination with amikacin for the treatment of experimental multiresistant Acinetobacter baumannii pneumonia.

Authors:  M Bernabeu-Wittel; C Pichardo; A García-Curiel; M E Pachón-Ibáñez; J Ibáñez-Martínez; M E Jiménez-Mejías; J Pachón
Journal:  Clin Microbiol Infect       Date:  2005-04       Impact factor: 8.067

2.  Missense mutations in PBP2A Affecting ceftaroline susceptibility detected in epidemic hospital-acquired methicillin-resistant Staphylococcus aureus clonotypes ST228 and ST247 in Western Switzerland archived since 1998.

Authors:  William L Kelley; Ambre Jousselin; Christine Barras; Emmanuelle Lelong; Adriana Renzoni
Journal:  Antimicrob Agents Chemother       Date:  2015-01-12       Impact factor: 5.191

3.  Characterization of methicillin-resistant Staphylococcus aureus displaying increased MICs of ceftaroline.

Authors:  Rodrigo E Mendes; Athanassios Tsakris; Helio S Sader; Ronald N Jones; Donald Biek; Pamela McGhee; Peter C Appelbaum; Klaudia Kosowska-Shick
Journal:  J Antimicrob Chemother       Date:  2012-03-07       Impact factor: 5.790

4.  Neutral β-Lactams Inactivate High Molecular Mass Penicillin-Binding Proteins of Class B1, Including PBP2a of MRSA.

Authors:  Kinjal Dave; Timothy Palzkill; R F Pratt
Journal:  ACS Med Chem Lett       Date:  2013-12-16       Impact factor: 4.345

5.  Population pharmacokinetics of piperacillin and tazobactam in critically ill patients undergoing continuous renal replacement therapy: application to pharmacokinetic/pharmacodynamic analysis.

Authors:  Eduardo Asín-Prieto; Alicia Rodríguez-Gascón; Iñaki F Trocóniz; Amaia Soraluce; Javier Maynar; José Ángel Sánchez-Izquierdo; Arantxazu Isla
Journal:  J Antimicrob Chemother       Date:  2013-08-01       Impact factor: 5.790

6.  Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection.

Authors:  Alasdair P MacGowan; Alan R Noel; Sharon Tomaselli; Karen E Bowker
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

7.  Reactions of all Escherichia coli lytic transglycosylases with bacterial cell wall.

Authors:  Mijoon Lee; Dusan Hesek; Leticia I Llarrull; Elena Lastochkin; Hualiang Pi; Bill Boggess; Shahriar Mobashery
Journal:  J Am Chem Soc       Date:  2013-02-21       Impact factor: 15.419

8.  Shared functional attributes between the mecA gene product of Staphylococcus sciuri and penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus.

Authors:  Cosimo Fuda; Maxim Suvorov; Qicun Shi; Dusan Hesek; Mijoon Lee; Shahriar Mobashery
Journal:  Biochemistry       Date:  2007-06-13       Impact factor: 3.162

Review 9.  The emergence of mecC methicillin-resistant Staphylococcus aureus.

Authors:  Gavin K Paterson; Ewan M Harrison; Mark A Holmes
Journal:  Trends Microbiol       Date:  2013-12-09       Impact factor: 17.079

10.  Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics.

Authors:  Jennifer Fishovitz; Alzoray Rojas-Altuve; Lisandro H Otero; Matthew Dawley; Cesar Carrasco-López; Mayland Chang; Juan A Hermoso; Shahriar Mobashery
Journal:  J Am Chem Soc       Date:  2014-07-02       Impact factor: 15.419

View more
  10 in total

1.  BPEI-Induced Delocalization of PBP4 Potentiates β-Lactams against MRSA.

Authors:  Melissa A Hill; Anh K Lam; Patricia Reed; Madeline C Harney; Beatrice A Wilson; Erika L Moen; Summer N Wright; Mariana G Pinho; Charles V Rice
Journal:  Biochemistry       Date:  2019-08-26       Impact factor: 3.162

2.  Conformational Dynamics in Penicillin-Binding Protein 2a of Methicillin-Resistant Staphylococcus aureus, Allosteric Communication Network and Enablement of Catalysis.

Authors:  Kiran V Mahasenan; Rafael Molina; Renee Bouley; María T Batuecas; Jed F Fisher; Juan A Hermoso; Mayland Chang; Shahriar Mobashery
Journal:  J Am Chem Soc       Date:  2017-01-27       Impact factor: 15.419

3.  Endless Resistance. Endless Antibiotics?

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Medchemcomm       Date:  2015-11-03       Impact factor: 3.597

4.  Peptidoglycan Cross-Linking Preferences of Staphylococcus aureus Penicillin-Binding Proteins Have Implications for Treating MRSA Infections.

Authors:  Veerasak Srisuknimit; Yuan Qiao; Kaitlin Schaefer; Daniel Kahne; Suzanne Walker
Journal:  J Am Chem Soc       Date:  2017-07-11       Impact factor: 15.419

5.  Exploration of the Structural Space in 4(3H)-Quinazolinone Antibacterials.

Authors:  Yuanyuan Qian; Giuseppe Allegretta; Jeshina Janardhanan; Zhihong Peng; Kiran V Mahasenan; Elena Lastochkin; Melissa Malia N Gozun; Sara Tejera; Valerie A Schroeder; William R Wolter; Rhona Feltzer; Shahriar Mobashery; Mayland Chang
Journal:  J Med Chem       Date:  2020-05-08       Impact factor: 7.446

6.  Unconventional Antibacterials and Adjuvants.

Authors:  Mayland Chang; Kiran V Mahasenan; Juan A Hermoso; Shahriar Mobashery
Journal:  Acc Chem Res       Date:  2021-01-29       Impact factor: 22.384

Review 7.  β-Lactam Resistance Mechanisms: Gram-Positive Bacteria and Mycobacterium tuberculosis.

Authors:  Jed F Fisher; Shahriar Mobashery
Journal:  Cold Spring Harb Perspect Med       Date:  2016-05-02       Impact factor: 6.915

8.  Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals.

Authors:  D O Andrey; P François; C Manzano; E J Bonetti; S Harbarth; J Schrenzel; W L Kelley; A Renzoni
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-15       Impact factor: 3.267

9.  Thermosensitive PBP2a requires extracellular folding factors PrsA and HtrA1 for Staphylococcus aureus MRSA β-lactam resistance.

Authors:  Mélanie Roch; Emmanuelle Lelong; Olesya O Panasenko; Roberto Sierra; Adriana Renzoni; William L Kelley
Journal:  Commun Biol       Date:  2019-11-15

10.  Fusidic acid resistance through changes in the dynamics of the drug target.

Authors:  Jennifer H Tomlinson; Arnout P Kalverda; Antonio N Calabrese
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-30       Impact factor: 11.205

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.